- Home
- GOSS vs NVX Comparison
GOSS vs NVX Comparison
Compare GOSS & NVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- NVX
- Stock Information
- Founded
- GOSS 2015
- NVX 2012
- Country
- GOSS United States
- NVX Australia
- Employees
- GOSS N/A
- NVX N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- NVX Industrial Machinery/Components
- Sector
- GOSS Health Care
- NVX Miscellaneous
- Exchange
- GOSS Nasdaq
- NVX Nasdaq
- Market Cap
- GOSS 214.7M
- NVX 176.5M
- IPO Year
- GOSS 2019
- NVX N/A
- Fundamental
- Price
- GOSS $0.96
- NVX $1.96
- Analyst Decision
- GOSS Strong Buy
- NVX Strong Buy
- Analyst Count
- GOSS 5
- NVX 1
- Target Price
- GOSS $9.20
- NVX $4.00
- AVG Volume (30 Days)
- GOSS 910.5K
- NVX 59.3K
- Earning Date
- GOSS 11-07-2024
- NVX 01-01-0001
- Dividend Yield
- GOSS N/A
- NVX N/A
- EPS Growth
- GOSS N/A
- NVX N/A
- EPS
- GOSS N/A
- NVX N/A
- Revenue
- GOSS $95,842,000.00
- NVX $6,875,112.00
- Revenue This Year
- GOSS N/A
- NVX $89.31
- Revenue Next Year
- GOSS N/A
- NVX $410.89
- P/E Ratio
- GOSS N/A
- NVX N/A
- Revenue Growth
- GOSS N/A
- NVX 19.05
- 52 Week Low
- GOSS $0.45
- NVX $1.40
- 52 Week High
- GOSS $1.60
- NVX $3.10
- Technical
- Relative Strength Index (RSI)
- GOSS 48.30
- NVX 51.84
- Support Level
- GOSS $0.93
- NVX $1.90
- Resistance Level
- GOSS $1.09
- NVX $2.49
- Average True Range (ATR)
- GOSS 0.05
- NVX 0.13
- MACD
- GOSS -0.01
- NVX 0.00
- Stochastic Oscillator
- GOSS 20.31
- NVX 22.06
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration and Mining, Battery Technology, and NOVONIX Anode Materials. Graphite Exploration and Mining segment is engaged in the exploration and development of high-grade flake graphite deposits. The NOVONIX Anode Materials segment develops and manufactures battery anode materials. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Technology segment generates maximum revenue for the company.